Kevin Feeley Sells 1,430 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 1,430 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $76.04, for a total value of $108,737.20. Following the transaction, the chief financial officer now owns 26,770 shares of the company's stock, valued at $2,035,590.80. The trade was a 5.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Kevin Feeley also recently made the following trade(s):

• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The stock was sold at an average price of $78.39, for a total transaction of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.
• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total value of $18,248.40.

GeneDx Trading Up 13.2 %

Shares of WGS traded up $10.47 during midday trading on Monday, hitting $89.61. 1,259,011 shares of the stock were exchanged, compared to its average volume of 808,279. GeneDx Holdings Corp. has a 52-week low of $2.80 and a 52-week high of $89.66. The stock has a fifty day simple moving average of $76.28 and a 200 day simple moving average of $51.22. The firm has a market cap of $2.46 billion, a P/E ratio of -28.81 and a beta of 2.03. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same quarter last year, the company earned ($0.82) EPS. The business's quarterly revenue was up 44.3% on a year-over-year basis. On average, research analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Wells Fargo & Company lifted their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. The Goldman Sachs Group boosted their target price on shares of GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Finally, Craig Hallum upped their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $59.33.

Institutional Trading of GeneDx

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in shares of GeneDx in the second quarter valued at about $2,362,000. Chartwell Investment Partners LLC acquired a new position in shares of GeneDx in the 3rd quarter worth approximately $1,722,000. Charles Schwab Investment Management Inc. increased its stake in GeneDx by 304.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company's stock valued at $6,240,000 after purchasing an additional 110,666 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in GeneDx in the third quarter worth about $325,000. Finally, Lisanti Capital Growth LLC bought a new stake in GeneDx in the third quarter valued at $1,554,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.